Granisetron controlled-release - Heron Therapeutics

Drug Profile

Granisetron controlled-release - Heron Therapeutics

Alternative Names: APF-530; Sustol

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator A.P. Pharma
  • Developer Heron Therapeutics
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Oct 2016 Launched for Chemotherapy induced nausea and vomiting (Combination therapy, Prevention) in USA (SC) (First global launch) before October 2016
  • 10 Aug 2016 Registered for Chemotherapy induced nausea and vomiting (Prevention, Combination therapy) in USA (SC) (First global approval)
  • 19 Feb 2016 Heron Therapeutics has patent protection for granisetron controlled-release in USA, Austria, Belgium, Canada, Denmark, the EU, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, Taiwan, and United Kingdom (Heron Therapeutics, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top